Matthew Biegler
Stock Analyst at Oppenheimer
(2.09)
# 2,999
Out of 5,239 analysts
91
Total ratings
35.71%
Success rate
-1.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APRE Aprea Therapeutics | Initiates: Outperform | $5 | $0.90 | +455.56% | 1 | May 7, 2026 | |
| RLAY Relay Therapeutics | Maintains: Outperform | $14 → $18 | $12.93 | +39.21% | 8 | Apr 28, 2026 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $36 → $50 | $34.87 | +43.39% | 7 | Feb 3, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $750 → $865 | $723.41 | +19.57% | 1 | Feb 2, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $13.97 | +243.59% | 10 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $21.16 | +112.67% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $8.83 | +69.88% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $8.13 | +170.60% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $15.96 | +75.44% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.89 | +323.28% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $3.88 | +80.41% | 1 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.30 | +291.30% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $16.47 | +871.46% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $9.57 | +370.22% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $134.94 | -14.78% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $28.12 | +88.48% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $4.28 | +367.29% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $8.70 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $6.96 | +101.15% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $10.55 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $2.25 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.28 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.78 | - | 2 | Dec 22, 2022 |
Aprea Therapeutics
May 7, 2026
Initiates: Outperform
Price Target: $5
Current: $0.90
Upside: +455.56%
Relay Therapeutics
Apr 28, 2026
Maintains: Outperform
Price Target: $14 → $18
Current: $12.93
Upside: +39.21%
Tyra Biosciences
Feb 3, 2026
Maintains: Outperform
Price Target: $36 → $50
Current: $34.87
Upside: +43.39%
Regeneron Pharmaceuticals
Feb 2, 2026
Reiterates: Outperform
Price Target: $750 → $865
Current: $723.41
Upside: +19.57%
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $13.97
Upside: +243.59%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $21.16
Upside: +112.67%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $8.83
Upside: +69.88%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $8.13
Upside: +170.60%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $15.96
Upside: +75.44%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.89
Upside: +323.28%
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $3.88
Upside: +80.41%
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $2.30
Upside: +291.30%
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $16.47
Upside: +871.46%
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $9.57
Upside: +370.22%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $134.94
Upside: -14.78%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $28.12
Upside: +88.48%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $4.28
Upside: +367.29%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $8.70
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $6.96
Upside: +101.15%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $10.55
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $2.25
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.28
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $0.78
Upside: -